News Image

KILL Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials

Provided By Business Wire

Last update: Apr 18, 2025

Aditxt, Inc. requests that their press release NewsItemId: 20250414955183 issued April 14, 2025 “Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials” be killed.

The release was issued in error by Aditxt, Inc.

A replacement release will not be issued at this time.

ADITXT INC

NASDAQ:ADTX (7/25/2025, 8:00:00 PM)

After market: 1.2099 +0.02 (+1.67%)

1.19

-0.07 (-5.56%)



Find more stocks in the Stock Screener

Follow ChartMill for more